Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-inferiority of Zoladex 10.8 mg vs 3.6 mg in premenopausal ER-positive advanced breast cancer
2005-004001-29Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of goserelin in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival at 24 weeks and Disease progression. Started Feb 2006; status: completed.
02
Drugs
goserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-004001-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004001-29.